Immuneering Corporation Increase (Decrease) in Other Operating Liabilities
Immuneering Corporation (IMRX) reported Increase (Decrease) in Other Operating Liabilities of -$77.05 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingLiabilities · last filed 2026-08-05
- Immuneering Corporation increase (decrease) in other operating liabilities for the quarter ending 2026-06-30 was $170.27K, a 11.16% increase year-over-year.
- Immuneering Corporation increase (decrease) in other operating liabilities for the quarter ending 2026-03-31 was -$247.32K.
- Immuneering Corporation increase (decrease) in other operating liabilities for the quarter ending 2025-12-31 was $211.42K, a 21.50% increase year-over-year.
- Immuneering Corporation increase (decrease) in other operating liabilities for the quarter ending 2025-09-30 was -$129.62K.
- Immuneering Corporation increase (decrease) in other operating liabilities for fiscal 2025 was $57.85K.
- Immuneering Corporation increase (decrease) in other operating liabilities for fiscal 2024 was -$26.11K, a 110.88% decline from fiscal 2023.
- Immuneering Corporation increase (decrease) in other operating liabilities for fiscal 2023 was $239.97K, a 1112.23% increase from fiscal 2022.
- Immuneering Corporation increase (decrease) in other operating liabilities for fiscal 2022 was $19.80K.
| Period end | Increase (Decrease) in Other Operating Liabilities 3 month | Increase (Decrease) in Other Operating Liabilities 6 month | Increase (Decrease) in Other Operating Liabilities 9 month | Increase (Decrease) in Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $170.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$77.05K 10-Q · filed 2026-08-05 | $134.37K derived: sum of 3 quarters · filed 2026-08-05 | $4.75K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$247.32K 10-Q · filed 2026-05-15 | -$35.90K derived: sum of 2 quarters · filed 2026-05-15 | -$165.52K derived: sum of 3 quarters · filed 2026-05-15 | -$12.34K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $211.42K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $81.81K derived: sum of 2 quarters · filed 2026-03-06 | $234.98K derived: sum of 3 quarters · filed 2026-08-05 | $57.85K 10-K · filed 2026-03-06 |
| 2025-09-30 | -$129.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $23.56K derived: sum of 2 quarters · filed 2026-08-05 | -$153.58K 10-Q · filed 2025-11-12 | $20.43K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $153.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$23.96K 10-Q · filed 2026-08-05 | $150.05K derived: sum of 3 quarters · filed 2026-08-05 | $119.47K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$177.13K 10-Q · filed 2026-05-15 | -$3.13K derived: sum of 2 quarters · filed 2026-05-15 | -$33.71K derived: sum of 3 quarters · filed 2026-05-15 | $32.90K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $174.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $143.42K derived: sum of 2 quarters · filed 2026-03-06 | $210.03K derived: sum of 3 quarters · filed 2026-03-06 | -$26.11K 10-K · filed 2026-03-06 |
| 2024-09-30 | -$30.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $36.02K derived: sum of 2 quarters · filed 2025-11-12 | -$200.11K 10-Q · filed 2025-11-12 | -$20.84K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $66.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$169.53K 10-Q · filed 2025-08-13 | $9.74K derived: sum of 3 quarters · filed 2025-08-13 | $63.91K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$236.14K 10-Q · filed 2025-05-05 | -$56.86K derived: sum of 2 quarters · filed 2025-05-05 | -$2.70K derived: sum of 3 quarters · filed 2025-05-05 | -$2.70K derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $179.27K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $233.44K derived: sum of 2 quarters · filed 2025-03-20 | $233.44K derived: sum of 3 quarters · filed 2025-03-20 | $239.97K 10-K · filed 2025-03-20 |
| 2023-09-30 | $54.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $54.16K derived: sum of 2 quarters · filed 2024-11-13 | $60.70K 10-Q · filed 2024-11-13 | $35.94K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.54K 10-Q · filed 2024-08-06 | -$18.23K derived: sum of 3 quarters · filed 2024-08-06 | -$30.78K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $6.54K 10-Q · filed 2024-05-07 | -$18.23K derived: sum of 2 quarters · filed 2024-05-07 | -$30.78K derived: sum of 3 quarters · filed 2024-05-07 | -$30.78K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$24.77K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$37.31K derived: sum of 2 quarters · filed 2024-03-01 | -$37.32K derived: sum of 3 quarters · filed 2024-03-01 | $19.80K 10-K · filed 2024-03-01 |
| 2022-09-30 | -$12.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$12.55K derived: sum of 2 quarters · filed 2023-11-09 | $44.56K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $57.11K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $57.11K 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |